- Home
- INBX vs ACTU Comparison
INBX vs ACTU Comparison
Compare INBX & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- ACTU
- Stock Information
- Founded
- INBX 2010
- ACTU 2015
- Country
- INBX United States
- ACTU United States
- Employees
- INBX N/A
- ACTU N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- ACTU
- Sector
- INBX Health Care
- ACTU
- Exchange
- INBX Nasdaq
- ACTU NYSE
- Market Cap
- INBX 168.1M
- ACTU 135.0M
- IPO Year
- INBX 2020
- ACTU 2024
- Fundamental
- Price
- INBX $11.18
- ACTU $10.35
- Analyst Decision
- INBX Hold
- ACTU Strong Buy
- Analyst Count
- INBX 1
- ACTU 1
- Target Price
- INBX N/A
- ACTU $20.00
- AVG Volume (30 Days)
- INBX 97.5K
- ACTU 71.1K
- Earning Date
- INBX 05-20-2025
- ACTU 05-21-2025
- Dividend Yield
- INBX 7.56%
- ACTU N/A
- EPS Growth
- INBX N/A
- ACTU N/A
- EPS
- INBX 112.62
- ACTU N/A
- Revenue
- INBX $200,000.00
- ACTU N/A
- Revenue This Year
- INBX N/A
- ACTU N/A
- Revenue Next Year
- INBX N/A
- ACTU N/A
- P/E Ratio
- INBX $0.10
- ACTU N/A
- Revenue Growth
- INBX N/A
- ACTU N/A
- 52 Week Low
- INBX $10.80
- ACTU $5.51
- 52 Week High
- INBX $18.95
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- INBX 38.27
- ACTU N/A
- Support Level
- INBX $10.90
- ACTU N/A
- Resistance Level
- INBX $12.60
- ACTU N/A
- Average True Range (ATR)
- INBX 0.86
- ACTU 0.00
- MACD
- INBX -0.03
- ACTU 0.00
- Stochastic Oscillator
- INBX 14.28
- ACTU 0.00
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.